On July 17, Genscript Biotech fell 5.18% in regular trading, trading at HKD 13.62/share, with turnover of HKD 81.64 million.

On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately $657 million for the quarter ended June 30, representing roughly 10% sequential growth from Q1's $597 million. This marks a notable deceleration from the 62% year-over-year growth recorded in Q1. Genscript had previously rallied over 5% on both July 13 and July 15, driven by CXO sector mid-year earnings catalysts, accumulating significant gains. Following the sales data release, profit-taking pressure emerged on July 16 and has continued into today's session.

The broader Life Sciences Tools & Services sector is under broad-based selling pressure, with WuXi AppTec down 5.37%, WuXi Biologics down 4.58%, Insilico down 10.4%, WuXi XDC down 7.34%, and JOINN down 9.61%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)